We were the first to assess the changes in serum survivin during treatment and show that increased survivin levels after chemotherapy were a marker of a better treatment outcome in MM, emphasizing the importance of survivin measurement before and after chemotherapy. Here, BIRC5 is linked to Miyoshi myopathy.